While retroviral therapy now sees patients survive into their seventies, latent residual infection still condemns the HIV-infected to life time therapy, chronic health problems and shortened lives. Compelling preclinical data now supported by two Phase II human trials indicate that Abivax's ABX464 could be the first drug to drain the latent HIV reservoir. With its novel mode of action ("MoA"), the drug may not only act to reduce or even eradicate residual infection untouched by existing antir
05 Oct 2017
HIV: Draining the reservoir; cooling the flame
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
HIV: Draining the reservoir; cooling the flame
Abivax SA (0RA9:LON) | 0 0 0.5% | Mkt Cap: 83.0m
- Published:
05 Oct 2017 -
Author:
Chris Redhead -
Pages:
31
While retroviral therapy now sees patients survive into their seventies, latent residual infection still condemns the HIV-infected to life time therapy, chronic health problems and shortened lives. Compelling preclinical data now supported by two Phase II human trials indicate that Abivax's ABX464 could be the first drug to drain the latent HIV reservoir. With its novel mode of action ("MoA"), the drug may not only act to reduce or even eradicate residual infection untouched by existing antir